Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital

This study evaluated the spread and possible changes in resistance patterns of ESKAPE bacteria to first-choice antibiotics from 2015 to 2019 at a third-level university hospital after persuasive stewardship measures were implemented. Isolates were divided into three groups (group 1, low drug-resistant; group 2, multidrug/extremely drug-resistant; and group 3, pan-resistant bacteria) and a chi-squared test (χ2) was applied to determine differences in their distributions. Among the 2,521 isolates, Klebsiella pneumoniae was the most frequently detected (31.1%). From 2015 to 2019, the frequency of isolates in groups 2 and 3 decreased from 70.1% to 48.6% (χ2 = 63.439; p < 0.0001). Stratifying isolates by bacterial species, for K. pneumoniae, the frequency of PDR isolates decreased from 20% to 1.3% (χ2 = 15.885; p = 0.003). For Acinetobacter baumannii, a statistically significant decrease was found in groups 2 and 3: from 100% to 83.3% (χ2 = 27.721; p < 0.001). Also, for Pseudomonas aeruginosa and Enterobacter spp., the frequency of groups 2 and 3 decreased from 100% to 28.3% (χ2 = 225.287; p < 0.001) and from 75% to 48.7% (χ2 = 15.408; p = 0.003), respectively. These results indicate that a program consisting of persuasive stewardship measures, which were rolled out during the time frame of our study, may be useful to control drug-resistant bacteria in a hospital setting.

[1]  Antimicrobial Resistance in the EU/EEA , 2022 .

[2]  M. Bassetti,et al.  Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study , 2021, BMC Infectious Diseases.

[3]  G. Ripabelli,et al.  Healthcare-Associated Infections and Antibiotics Consumption: A Comparison of Point Prevalence Studies and Intervention Strategies , 2021, Hospital topics.

[4]  Songzhe He,et al.  Distribution and Carbapenem Susceptibility of Gram-Negative ESKAPE Pathogens in Hospitalized Patients from Three General Hospitals. , 2021, Clinical laboratory.

[5]  S. K. Mishra,et al.  Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital , 2019, Infection and drug resistance.

[6]  G. Lina,et al.  Trends in Antibiotic Consumption and Resistance in France Over 20 Years: Large and Continuous Efforts but Contrasting Results , 2020, Open forum infectious diseases.

[7]  A. Kharat,et al.  Retrospective Analysis on Antimicrobial Resistance Trends and Prevalence of β-lactamases in Escherichia coli and ESKAPE Pathogens Isolated from Arabian Patients during 2000–2020 , 2020, Microorganisms.

[8]  Veena P Menon,et al.  Clinical efficacy and pharmacokinetics of CMS and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant gram-negative bacterial infections-A Prospective Observational Study. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  M. Antonelli,et al.  Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections , 2020, Annals of Intensive Care.

[10]  S. Beatson,et al.  Antimicrobial Resistance in ESKAPE Pathogens , 2020, Clinical Microbiology Reviews.

[11]  K. Peck,et al.  Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. Torti,et al.  Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review about its efficacy and safety for off-label indications. , 2020, International journal of antimicrobial agents.

[13]  G. Ripabelli,et al.  Molecular Epidemiological Insights into Colistin-Resistant and Carbapenemases-Producing Clinical Klebsiella pneumoniae Isolates , 2019, Infection and drug resistance.

[14]  L. Marconi,et al.  Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections , 2019, Open forum infectious diseases.

[15]  P. Navalesi,et al.  Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. , 2019, The Journal of antimicrobial chemotherapy.

[16]  P. Courvalin,et al.  Population-based inference of aminoglycoside resistance mechanisms in Escherichia coli , 2019, EBioMedicine.

[17]  A. Nicolucci,et al.  Control of Gram-negative multi-drug resistant microorganisms in an Italian ICU: Rapid decline as a result of a multifaceted intervention, including conservative use of antibiotics. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  Sameer S. Kadri,et al.  External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals. , 2019, Open forum infectious diseases.

[19]  M. L. Ciofi Degli Atti,et al.  [Good practices for the surveillance and control of antimicrobial resistance]. , 2019, Epidemiologia e prevenzione.

[20]  S. Antinori,et al.  Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase–producing K. pneumoniae , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  W. Dunne,et al.  Developmental roadmap for antimicrobial susceptibility testing systems , 2018, Nature Reviews Microbiology.

[22]  Sameer S. Kadri,et al.  Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  G. Kahlmeter,et al.  Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  A. Focà,et al.  Control of carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit of a teaching hospital in Southern Italy , 2016, BMC Infectious Diseases.

[25]  S. Pournaras,et al.  Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance. , 2016, International journal of antimicrobial agents.

[26]  Matthew H Samore,et al.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Karen C Carroll,et al.  The Use of a Combination Antibiogram to Assist with the Selection of Appropriate Antimicrobial Therapy for Carbapenemase-Producing Enterobacteriaceae Infections , 2015, Infection Control &#x0026; Hospital Epidemiology.

[28]  M. Kollef,et al.  Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy* , 2015, Critical care medicine.

[29]  A. Armaganidis,et al.  Bloodstream infections in ICU with increased resistance: epidemiology and outcomes. , 2015, Minerva anestesiologica.

[30]  Development of a urinary-specific antibiogram for gram-negative isolates: impact of patient risk factors on susceptibility. , 2014, American journal of infection control.

[31]  L. Leibovici,et al.  Editorial commentary: combination therapy for Pseudomonas aeruginosa bacteremia: where do we stand? , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Deverick J. Anderson,et al.  Ability of an Antibiogram to Predict Pseudomonas aeruginosa Susceptibility to Targeted Antimicrobials Based on Hospital Day of Isolation , 2012, Infection Control &#x0026; Hospital Epidemiology.

[33]  Benjamin Vekhter,et al.  Demonstration of the Weighted-Incidence Syndromic Combination Antibiogram: An Empiric Prescribing Decision Aid , 2012, Infection Control &#x0026; Hospital Epidemiology.

[34]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[35]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  L. Rice Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. , 2008, The Journal of infectious diseases.

[37]  D. Livermore,et al.  Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. , 2001, The Journal of antimicrobial chemotherapy.

[38]  D. Shlaes Role of antimicrobial stewardship in prevention and control of antibiotic resistance , 1999, Current infectious disease reports.